ARCHIVED: NOT AVAILABLE FOR CREDIT
Work Up of Acute Leukemia

 

Laboratory evaluation of acute leukemia although critical, is complex and is constantly evolving due to advancement in understanding the molecular basis of leukemia. Its implication is not only for diagnosis, but also for therapeutic and prognostic purposes. In recognition of the complexity of these testing algorithm, College of American Pathologists and American Society of Hematology have come up with guidelines to help clinician and pathologist in initial evaluation of acute leukemia. This presentation focuses on the classification, sample requirements and the tests needed on every patients as well as on a subset of patients. Prognostic and therapeutic implications of these newer molecular tests would be discussed briefly.

Originally presented on February 12, 2019, in Park City, Utah.

Lecture Presenter

Archana Agarwal, MD

Archana Agarwal, MD

Associate Professor of Pathology
University of Utah School of Medicine
Medical Director, Hematopathology and Special Genetics
ARUP Laboratories

Dr. Agarwal is an associate professor of pathology at the University of Utah School of Medicine. She received her MD at Delhi University in India and was a postdoctoral research scholar at the University of Iowa. She served as a pathology resident, a hematopathology fellow, and a molecular genetics pathology fellow at the University of Utah School of Medicine. Dr. Agarwal is board certified in hematopathology, anatomic pathology, and clinical pathology. She is also a member of several professional societies, including the College of American Pathologists and the American Society for Clinical Pathology. Dr. Agarwal’s research interests include red-cell enzymopathies, hemoglobinopathies, and molecular hematopathology.

Objectives

After this presentation, participants will be able to:

  • Discuss the updated testing guidelines for acute leukemia from College of American Pathologist/American Society of Hematology
  • Describe the samples and tests needed at the time of initial evaluation on all patients
  • Discuss the tests needed on a subset of acute leukemia patients
  • List the prognostic/therapeutic implications of newer molecular tests in acute leukemia
  • Discuss briefly the newly approved targeted therapies

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories